
How to Request a Genetic Test
We're here to guide you every step of the way—from choosing the test to interpreting the results—with the support of our team of geneticists and a certified laboratory.
From the Clinical Case to the Genetic Diagnosis
A simple process for healthcare professionals, with a leading geneticist who guides you every step of the way.
- 1
Inquiry
Our geneticists will help you choose the most appropriate test for each patient.
- 2
Application
Online via Genome Lab at
Download sheet
or using the application form, along with the informed consent form. - 3
Sample
Sample shipping at no additional cost from your facility.
- 4
Report
Results report interpreted
by our geneticists.

Genetic counselling
Dr. Leyre Larzabal will guide you through every stage of the process. She will work with you to determine whether the test is appropriate, interpret the results within their clinical and family context, and advise you on the next steps.
- Training
- Ph.D. in Biology from the University of Navarra; Bachelor's degrees in Biology and Biochemistry
- Accreditation
- Public Health Biologist certified by the General Council of Official Associations of Biologists
- Experience
- More than 10 years of experience in genetic diagnostics and high-throughput sequencing
- Companies
- Member of the Spanish Association of Human Genetics (AEGH) and the European Society of Human Genetics (ESHG)
What We Need
Three steps to get started with the test, which you can complete online at Genome Lab or on paper. If you have any questions about the sample or the test, please contact us before sending it in.
Application form
Patient and referring physician information, requested test, and clinical information: reason for the visit, phenotype, and family history.
Informed Consent
Signed by the patient or his or her legal representative, as indicated on the application form.
Sample
Peripheral blood in EDTA, saliva, or extracted DNA. Ship at room temperature or refrigerated, at no additional cost from your facility.
Online Application with Genome Lab
Submit the request, attach the clinical information and the informed consent form, and check the status
for each study from our platform, which complies with the GDPR and the standard
Report of results
A clear and comprehensive clinical report, with the findings highlighted at the beginning and all supporting evidence included. It is signed by licensed clinical geneticists who are members of the AEGH.
- BackgroundClinical suspicion and reason for the study.
- ResultKey finding highlighted at the beginning of the report.
- Identified VariantsGene, zygosity, and allele frequency; RefSeq transcript; HGVS nomenclature; dbSNP ID; and ACMG classification.
- InterpretationEvidence for each variant in clinical and population databases, in silico prediction and the literature, and CNV analysis.
- RecommendationsDescription of the disease, segregation studies, reproductive risk, and family history.
- Secondary FindingsACMG-actionable variants, only with informed consent.
- AppendicesACMG criteria applied to each variant, depth and coverage, genes analyzed along with their transcripts, methodology, limitations, and references.
- Code
- DG_13.003 | DG Retinitis Pigmentosa
- Sample
- EDTA Blood
- Service
- Ophthalmology
- Optional
- Dr. XX
Assuming that the variants have been inherited in a trans manner, this result would confirm the clinical diagnosis. Segregation analysis is recommended for both parents.
AEGH: Spanish Association of Human Genetics.
Classification of Variants
We classify each variant according to the recommendations of the American College of Medical Genetics and Genomics (ACMG), incorporating population databases, in silico predictors, and clinical information.
- PathogenicCausing disease or associated with an increased risk of developing it.
- Probably pathogenicMore than a 90% probability of causing disease.
- Uncertain significance (VUS)Insufficient evidence to classify it. It will be reevaluated over time.
- Probably benignMost likely has no effect on health.
- BenignNo known health effects.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):
Reanalysis and Reevaluation
of VUS
Our understanding of genetics advances every year: new genes are identified, and new evidence allows us to reclassify variants. That is why a result that is inconclusive today may have an answer tomorrow.
- 01
Evidence Tracking
We periodically review the scientific literature and clinical and population-based databases.
- 02
Reevaluation at 12 months
Variants with uncertain significance are reevaluated 12 months after the report is issued, applying the ACMG criteria to the new evidence available.
- 03
Notice to the Physician
If the classification changes, we issue a new report. If not, we send an email to the requesting physician confirming the review.
- 04
Reanalysis of the data
Exome data are stored and can be reanalyzed in the event of new symptoms, an expanded study, or a diagnosis in a family member.
Frequently Asked Questions
Who can request a study?
Tests must be ordered by a healthcare professional, who receives the report and interprets it within the patient's clinical context.
How do I know which program to apply for?
Our geneticists will help you choose the most appropriate test based on your phenotype, family history, and clinical suspicion. You can also browse our catalog by specialty or search for a specific gene.
What is the deadline for submitting the report?
It depends on the test. Targeted exome sequencing has a turnaround time of 30 business days, and tests using other molecular techniques take 20 to 30 business days.
How do I send the sample?
We coordinate sample collection at your facility at no additional cost. The sample can be shipped at room temperature or refrigerated, along with the request form and the informed consent form.
What happens if the result includes a variant with an uncertain meaning?
Variants with uncertain significance are reevaluated 12 months after the report is issued. If their classification changes, we issue a new report; if not, we send an email to the requesting physician confirming that the variant has been reviewed and that its classification has not changed.
Can a study that has already been conducted be reanalyzed?
Yes. The exome data are stored and can be reanalyzed if new symptoms appear, if you wish to expand the study to include other genes, or if a family member is diagnosed with an inherited disease.
Shall we talk about your patient?
We'll answer your questions about the most appropriate genetic test or send you a no-obligation quote.
- Response within 24 business hours
- Advice from our geneticists on choosing a test
- Sample shipping at no additional cost from your facility